The estimated Net Worth of Matthew R. Henn is at least $3.41 Milion dollars as of 15 August 2024. Matthew Henn owns over 2,813 units of Seres Therapeutics Inc stock worth over $71,579 and over the last 5 years he sold MCRB stock worth over $2,482,596. In addition, he makes $859,452 as Executive Vice President i Chief Scientific Officer at Seres Therapeutics Inc.
Sign up
Matthew Henn MCRB stock SEC Form 4 insiders trading
Matthew has made over 6 trades of the Seres Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,813 units of MCRB stock worth $2,954 on 15 August 2024.
The largest trade he's ever made was selling 91,812 units of Seres Therapeutics Inc stock on 1 December 2020 worth over $2,482,596. On average, Matthew trades about 9,908 units every 128 days since 2020. As of 15 August 2024 he still owns at least 68,170 units of Seres Therapeutics Inc stock.
You can see the complete history of Matthew Henn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Henn biography
Dr. Matthew R. Henn Ph.D. serves as Executive Vice President, Chief Scientific Officer of the Company. Since joining our company at its launch in June 2012, he has held positions of increasing seniority, most recently as Executive Vice President, Head of Discovery and Microbiome R&D from January 2018 to February 2019, and previously as Senior Vice President, Head of Discovery and Bioinformatics from June 2012 to January 2018. Prior to joining our company, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. He currently serves on the scientific advisory boards of the Forsyth Institute and Growcentia, Inc., an agricultural microbiome company. Dr. Henn earned his B.S. in Ecology and Evolutionary Sciences from the University of New Hampshire and his Ph.D. in Ecosystem Sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a NSF Postdoctoral Fellow in Microbiology at Duke University.
What is the salary of Matthew Henn?
As the Executive Vice President i Chief Scientific Officer of Seres Therapeutics Inc, the total compensation of Matthew Henn at Seres Therapeutics Inc is $859,452. There are 3 executives at Seres Therapeutics Inc getting paid more, with Eric Shaff having the highest compensation of $2,032,550.
How old is Matthew Henn?
Matthew Henn is 45, he's been the Executive Vice President i Chief Scientific Officer of Seres Therapeutics Inc since 2019. There are 18 older and 1 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
What's Matthew Henn's mailing address?
Matthew's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Insiders trading at Seres Therapeutics Inc
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par... oraz Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
What does Seres Therapeutics Inc do?
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
What does Seres Therapeutics Inc's logo look like?
Complete history of Matthew Henn stock trades at Seres Therapeutics Inc
Seres Therapeutics Inc executives and stock owners
Seres Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Eric Shaff,
President, Chief Executive Officer, Director -
Eric D. Shaff M.B.A.,
Pres, CEO & Director -
Thomas DesRosier,
Chief Legal Officer, Executive Vice President and Secretary -
Matthew Henn,
Executive Vice President, Chief Scientific Officer -
Thomas J. DesRosier,
Chief Legal Officer, Exec. VP & Sec. -
Dr. David S. Ege Ph.D.,
Exec. VP & Chief Technology Officer -
Richard Kender,
Independent Director -
Kurt Graves,
Independent Director -
Meryl Zausner,
Independent Director -
Willard Dere,
Independent Director -
Gregory Behar,
Independent Director -
Dennis Ausiello,
Independent Director -
Stephen Berenson,
Independent Chairman of the Board -
David Ege,
Executive Vice President, Chief Technology Officer -
Jayne Gansler,
Chief People Officer, Executive Vice President -
Terri Young,
Executive Vice President, Chief Commercial and Strategy Officer -
Lisa von Moltke,
Executive Vice President, Chief Medical Officer -
Paul Biondi,
Independent Director -
Carlo Tanzi,
Head of Investor Relations and Corporate Communications -
John Aunins,
Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer -
Marcus Chapman,
Senior Vice President - Finance and Principal Financial and Accounting Officer -
Dr. John G. Aunins Ph.D.,
Sr. Advisor -
Dr. Matthew R. Henn Ph.D.,
Exec. VP & Chief Scientific Officer -
David A. Arkowitz M.B.A.,
Exec. VP, CFO & Head of Bus. Devel. -
James R. Weston,
Sr. VP of Regulatory Affairs -
Jayne M. Gansler,
Exec. VP & Chief People Officer -
Jeff York,
VP of HR -
Noubar Flagship Ventures Fu...,
-
Peter Barton Hutt,
Director -
Michele Trucksis,
See Remarks -
David N Cook,
See Remarks -
Noubar Afeyan,
Director -
Health Science Us Holdings,...,
-
Lorence H. Kim,
Director -
Wael Hashad,
EVP & Chief Commercial Officer -
Teresa L. Young,
See Remarks -
Paula Cloghessy,
See Remarks -
Marella Thorell,
See Remarks -
Roger Pomerantz,
President and CEO -
Kevin Horgan,
Chief Medical Officer and EVP -
Werner Cautreels,
Director -
Noubar Flagship Ventures Fu...,
-
Ventures Fund Iv General Pa...,
-
Health Ltp Fund General Par...,
-
David Arkowitz,
Chief Financial Officer -
Health Ltp Fund General Par...,
-
Claire Fraser,